Instil Bio Stock Today
| TIL Stock | USD 39.95 8.53 17.59% |
Performance15 of 100
| Odds Of DistressLess than 48
|
Instil Bio is selling for 39.95 as of the 8th of October 2024. This is a 17.59% down since the beginning of the trading day. The stock's lowest day price was 39.35. Instil Bio has 48 percent odds of going through some form of financial distress in the next two years but had a very good returns during the last 90 days. Equity ratings for Instil Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of September 2024 and ending today, the 8th of October 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of March 2021 | Category Healthcare | Classification Health Care |
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas. Instil Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 6.5 M outstanding shares of which 259.47 K shares are at this time shorted by investors with about 0.7 days to cover. More on Instil Bio
Moving together with Instil Stock
Moving against Instil Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Instil Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Old Names | [TIPTEL, Trilogy International Limited] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, NASDAQ Composite, NASDAQ Composite Total, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsInstil Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Instil Bio's financial leverage. It provides some insight into what part of Instil Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Instil Bio (TIL) is traded on NASDAQ Exchange in USA. It is located in 3963 Maple Avenue, Dallas, TX, United States, 75219 and employs 49 people. Instil Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 315.31 M. Instil Bio runs under Biotechnology sector within Health Care industry. The entity has 6.5 M outstanding shares of which 259.47 K shares are at this time shorted by investors with about 0.7 days to cover.
Instil Bio has about 354.61 M in cash with (82.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.73.
Check Instil Bio Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Instil Bio is $315.31 Million. The majority of Instil Bio outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Instil Bio to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Instil Bio. Please pay attention to any change in the institutional holdings of Instil Bio as this could imply that something significant has changed or is about to change at the company. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Instil Ownership Details
Instil Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Advisers, Llc | 2024-06-30 | 28.1 K | |
| Two Sigma Investments Llc | 2024-06-30 | 23.8 K | |
| State Street Corp | 2024-06-30 | 12.2 K | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 5.1 K | |
| Northwestern Mutual Wealth Management Co | 2024-06-30 | 625 | |
| Jones Financial Companies Lllp | 2024-06-30 | 500 | |
| Barclays Plc | 2024-06-30 | 479 | |
| Royal Bank Of Canada | 2024-06-30 | 171 | |
| Citigroup Inc | 2024-06-30 | 115 | |
| Vivo Capital, Llc | 2024-06-30 | 624.3 K | |
| Cpmg Inc | 2024-06-30 | 410.9 K |
Instil Bio Historical Income Statement
Instil Stock Against Markets
Instil Bio Corporate Management
| Sandeep MD | CFO Officer | Profile | |
| Timothy Moore | Chief Officer | Profile | |
| Bronson Crouch | Chairman CEO | Profile | |
| Sumita JD | Compliance, Legal | Profile | |
| Mark Dudley | Chief Officer | Profile | |
| Robert MBBS | Head Development | Profile |
Additional Information and Resources on Investing in Instil Stock
When determining whether Instil Bio is a strong investment it is important to analyze Instil Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Instil Bio's future performance. For an informed investment choice regarding Instil Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Instil Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Instil Stock please use our How to buy in Instil Stock guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Instil Bio. If investors know Instil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Instil Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (18.39) | Return On Assets (0.12) | Return On Equity (0.49) |
The market value of Instil Bio is measured differently than its book value, which is the value of Instil that is recorded on the company's balance sheet. Investors also form their own opinion of Instil Bio's value that differs from its market value or its book value, called intrinsic value, which is Instil Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Instil Bio's market value can be influenced by many factors that don't directly affect Instil Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Instil Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Instil Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Instil Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.